Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency De… (NCT06395428) | Clinical Trial Compass
RecruitingPhase 4
Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department
United States75 participantsStarted 2024-07-09
Plain-language summary
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of back pain. A total of 150 patients age 18-65 presenting to the emergency department with chief complaint of backpain will be enrolled from April 2024 - April 2025. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 - 65 years old
* Presenting to the Bronson ED with a chief complaint of acute, non-traumatic back pain
* VAS score \>5 cm
Exclusion Criteria:
* Back pain due to traumatic injury
* Experiencing saddle anesthesia
* Has bowel or bladder dysfunction
* Has an abnormal neurological exam
* Requires imaging in ED
* Has a Glascow coma score \<15
* Has one or more abnormal vital signs:
HR\>120, SBP\>180 or \<90, temperature \>38°, O2 saturation\<92%
* Has an allergy to ketorolac or haloperidol
* Has a known diagnosis of Lewy Body Dementia
* Has a known diagnosis of glaucoma.
* Is known to be pregnant or breastfeeding
* Is a prisoner or ward of the state
* Is unable to consent for themselves/ non-english speaking
* In the opinion of the attending physician or investigator the patient should not participate in the research
What they're measuring
1
Visual Analog Scale (VAS)
Timeframe: 30, 60, and 90 minutes after drug administration
Trial details
NCT IDNCT06395428
SponsorWestern Michigan University School of Medicine